(Boursier.com) — Valbiotis announces the selection of the Phase II/III clinical study Reverse-IT for an oral presentation at the annual congress of the European Association for the Study of Diabetes (EASD), which takes place from October 2 to 6, 2023 in Hamburg ( Germany).
In the field of early glycemic disorders, the REVERSE-IT study conducted in partnership with Nestlé Health Science constitutes a world first for a non-drug active substance, both in terms of its scale (636 volunteers) and the number of centers involved internationally (52 centers in 7 countries). The full positive results, communicated on September 11, 2023 (press release of September 11), demonstrated the remarkable effectiveness of the active substance TOTUM-63.
The detailed protocol as well as the complete characteristics of the population included, at the start of the study, will be presented during an oral session scheduled for October 3 from 12:30 p.m. to 1:30 p.m.
©2023 Boursier.com